H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options
The 2021 World Health Organization Classification of Tumors of the Central Nervous System reflected advances in understanding of the roles of oncohistones in gliomagenesis with the introduction of the H3.3-G34R/V mutant glioma to the already recognized H3-K27M altered glioma, which represent the dia...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/7/2002 |
| _version_ | 1797590196232912896 |
|---|---|
| author | Anthony V. Nguyen Jose M. Soto Sarah-Marie Gonzalez Jennifer Murillo Eric R. Trumble Frank Y. Shan Jason H. Huang |
| author_facet | Anthony V. Nguyen Jose M. Soto Sarah-Marie Gonzalez Jennifer Murillo Eric R. Trumble Frank Y. Shan Jason H. Huang |
| author_sort | Anthony V. Nguyen |
| collection | DOAJ |
| description | The 2021 World Health Organization Classification of Tumors of the Central Nervous System reflected advances in understanding of the roles of oncohistones in gliomagenesis with the introduction of the H3.3-G34R/V mutant glioma to the already recognized H3-K27M altered glioma, which represent the diagnoses of pediatric-type diffuse hemispheric glioma and diffuse midline glioma, respectively. Despite advances in research regarding these disease entities, the prognosis remains poor. While many studies and clinical trials focus on H3-K27M-altered-glioma patients, those with H3.3-G34R/V mutant gliomas represent a particularly understudied population. Thus, we sought to review the current knowledge regarding the molecular mechanisms underpinning the gliomagenesis of H3.3-G34R/V mutant gliomas and the diagnosis, treatment, long-term outcomes, and possible future therapeutics. |
| first_indexed | 2024-03-11T01:17:06Z |
| format | Article |
| id | doaj.art-dcaf970b8e0644c2ba5363cbf4e9a08b |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T01:17:06Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-dcaf970b8e0644c2ba5363cbf4e9a08b2023-11-18T18:28:03ZengMDPI AGBiomedicines2227-90592023-07-01117200210.3390/biomedicines11072002H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic OptionsAnthony V. Nguyen0Jose M. Soto1Sarah-Marie Gonzalez2Jennifer Murillo3Eric R. Trumble4Frank Y. Shan5Jason H. Huang6Department of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USADepartment of Neurosurgery, Baylor Scott and White Medical Center, Temple, TX 76508, USAThe 2021 World Health Organization Classification of Tumors of the Central Nervous System reflected advances in understanding of the roles of oncohistones in gliomagenesis with the introduction of the H3.3-G34R/V mutant glioma to the already recognized H3-K27M altered glioma, which represent the diagnoses of pediatric-type diffuse hemispheric glioma and diffuse midline glioma, respectively. Despite advances in research regarding these disease entities, the prognosis remains poor. While many studies and clinical trials focus on H3-K27M-altered-glioma patients, those with H3.3-G34R/V mutant gliomas represent a particularly understudied population. Thus, we sought to review the current knowledge regarding the molecular mechanisms underpinning the gliomagenesis of H3.3-G34R/V mutant gliomas and the diagnosis, treatment, long-term outcomes, and possible future therapeutics.https://www.mdpi.com/2227-9059/11/7/2002neuro-oncologyneurosurgical oncologyneurosurgerygliomadiffuse hemispheric gliomaH3G34 |
| spellingShingle | Anthony V. Nguyen Jose M. Soto Sarah-Marie Gonzalez Jennifer Murillo Eric R. Trumble Frank Y. Shan Jason H. Huang H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options Biomedicines neuro-oncology neurosurgical oncology neurosurgery glioma diffuse hemispheric glioma H3G34 |
| title | H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options |
| title_full | H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options |
| title_fullStr | H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options |
| title_full_unstemmed | H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options |
| title_short | H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic Options |
| title_sort | h3g34 mutant gliomas a review of molecular pathogenesis and therapeutic options |
| topic | neuro-oncology neurosurgical oncology neurosurgery glioma diffuse hemispheric glioma H3G34 |
| url | https://www.mdpi.com/2227-9059/11/7/2002 |
| work_keys_str_mv | AT anthonyvnguyen h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT josemsoto h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT sarahmariegonzalez h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT jennifermurillo h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT ericrtrumble h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT frankyshan h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions AT jasonhhuang h3g34mutantgliomasareviewofmolecularpathogenesisandtherapeuticoptions |